NASDAQ$RXRX
Recursion Pharmaceuticals Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported business updates and financial results.
Recursion Pharmaceuticals reported a revenue of $10.9 million and a net loss of $93.0 million for the fourth quarter of 2023. The company's cash and cash equivalents totaled $391.6 million as of December 31, 2023.
- Multiple clinical programs from Recursion's first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025.
- In-licensed a program (Target Epsilon) that emerged from the fibrosis collaboration with Bayer.
- Began incorporating causal AI models into the Recursion OS trained using data from Tempus.
- Phase 2 SYCAMORE clinical trial is expected to share data in Q3 2024.
Headline financials
Revenue & EPS history
Recursion Pharmaceuticals · Revenue · Quarterly
$10.9M
Revenue by segment
Recursion Pharmaceuticals · $1 total across 1 segment · Q2 2023
- Grant Revenue$1—100.0%
Forward guidance
Recursion expects to share Phase 2 data for REC-994 in Q3 2024, Phase 2 safety and preliminary efficacy data for REC-2282 in Q4 2024, and Phase 2 safety and preliminary efficacy data for REC-4881 in H1 2025. They also anticipate initiating a Phase 2 study for REC-3964 in 2024 and submitting an IND for their RBM39 program in H2 2024.
Tailwinds
- REC-994 Phase 2 data readout expected in Q3 2024.
- REC-2282 Phase 2 safety and preliminary efficacy data expected in Q4 2024.
- REC-4881 Phase 2 safety and preliminary efficacy data expected in H1 2025.
- REC-3964 Phase 2 study to be initiated in 2024.
- RBM39 IND submission expected in H2 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-3.1%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+7.2%
Avg return
30 days after
32%
8 / 25 earnings
Positive
+11.6%
Q1 2023
Best reaction
-16.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | -3.3% | -1.8% | |
| Q4 2025 | +6.5% | +2.8% | -16.7% | |
| Q3 2025 | -0.6% | -9.8% | -5.8% | |
| Q1 2025 | -16.5% | -24.0% | -13.9% | |
| Q4 2024 | -12.3% | -16.9% | -29.6% | |
| Q3 2024 | +1.6% | +15.0% | +17.4% | |
| Q2 2024 | -1.3% | +2.7% | -7.1% | |
| Q1 2024 | +0.1% | +17.0% | -0.9% | |
| Q4 2023 | -12.3% | -13.2% | -32.5% | |
| Q3 2023 | -3.0% | +14.7% | +35.0% | |
| Q2 2023 | -0.5% | -13.2% | -24.2% | |
| Q1 2023 | +11.6% | +2.5% | +75.8% | |
| Q4 2022 | +7.1% | +11.4% | -11.3% | |
| Q3 2022 | +8.9% | +32.8% | -0.6% | |
| Q2 2022 | +4.4% | +27.4% | +35.8% | |
| Q1 2022 | -9.4% | +1.4% | +34.4% | |
| Q4 2019 | -0.7% | -1.7% | -14.2% | |
| Q4 2021 | -0.7% | -1.7% | -14.2% | |
| Q3 2020 | -9.1% | -4.3% | -3.2% | |
| Q3 2021 | -9.1% | -4.3% | -3.2% | |
| Q2 2020 | -10.8% | -17.2% | +23.1% | |
| Q2 2021 | -10.8% | -17.2% | +23.1% | |
| Q1 2020 | -7.1% | -3.6% | +37.8% | |
| Q1 2021 | -7.1% | -3.6% | +37.8% | |
| Q4 2020 | -7.1% | -3.6% | +37.8% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro